We appreciate your participation and energy during the virtual CPIC Annual Meeting during IDWeek and are looking forward to ramping up our research efforts. As we move forward, please be thinking about next year’s competitive renewal application. We will be looking for suggestions about how to build on our current research projects and for new project ideas that are related to CPIC areas of interest.

We are pleased to announce that our Neonatal EV Sepsis natural history study is now active at 19 sites. Congratulations to Cook Children’s Hospital (Dr. Susan Whitworth, PI) for enrolling the first subject on the DMID 19-0026-(EVNH) study. We will be following these neonates, who present with clinical signs and laboratory data consistent with viral sepsis, for three months to determine morbidity and mortality, and to explore quantitative changes in the causative virus over time.

We are pleased to announce that our Neonatal EV Sepsis protocol is active at 12 sites. In addition, we are hopeful that our Valacyclovir PK and Longitudinal CMV protocols will be initiated by late 2020 or early 2021. The Valacyclovir PK study synopsis was reviewed by the NIAID/DMID Clinical Science Review Committee on 10/20 and received favorable feedback. Full comments are expected soon, clearing the way for protocol development and selection of the 5 sites. More on site selection to follow.

This eBrief detailz the status of our CPIC studies, including the Neonatal Enterovirus study that will be ready to start once the COVID-19 shutdown lifts as well as the other studies that are in varying stages of development. It also will provide new timelines for the educational and pilot funding activities of our Consortium. Once we are through this – and we will be through it at some point! – I have no doubt that this network of collaborators will emerge stronger, more dedicated, and more energetic than ever before. And, given the great things we have already accomplished together over the past years and decades, that will be a really fun period to be entering!

We are excited that CPIC will soon begin implementing our research projects as part of the Rare Diseases Clinical Research Network (RDCRN). As we begin the work of our Consortium, we want to distribute important information and updates to all sites in a consistent and concise way. We will have monthly calls with PIs and study teams to discuss protocols once the studies are active, but will use this eBrief format to share additional information. Please note that each issue will include the status of our four research projects, as well as updates related to the Career Enhancement Core and the Pilot and Feasibility Core. We will also include contact information for key personnel, as well as any relevant regulatory or financial updates.

The July 2022 CPIC eBrief includes information on the consortium's latest pilot recipient, a partnership with Herpes Cure Advocacy (HCA), a protocol status update, and more.